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Abstract
Objective
Degenerative cervical myelopathy [DCM] is a disabling and increasingly prevalent group of
diseases. Heterogeneous reporting of trial outcomes limits effective inter-study comparison
and optimisation of treatment. This is recognised in many fields of healthcare research. The
present study aims to assess the heterogeneity of outcome reporting in DCM as the premise
for the development of a standardised reporting set.
Methods
A systematic review of MEDLINE and EMBASE databases, registered with PROSPERO
(CRD42015025497) was conducted in accordance with PRISMA guidelines. Full text arti-
cles in English, with >50 patients (prospective) or >200 patients (retrospective), reporting
outcomes of DCM were eligible.
Results
108 studies, assessing 23,876 patients, conducted world-wide, were identified. Reported
outcome themes included function (reported by 97, 90% of studies), complications (reported
by 56, 52% of studies), quality of life (reported by 31, 29% of studies), pain (reported by 29,
27% of studies) and imaging (reported by 59, 55% of studies). Only 7 (6%) studies consid-
ered all of domains in a single publication. All domains showed variability in reporting.
Conclusions
Significant heterogeneity exists in the reporting of outcomes in DCM. The development of a
consensus minimum dataset will facilitate future research synthesis.
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Introduction
Chronic compression of the cervical spinal cord can arise from a range of disease processes,
including spondylosis, stenosis, disc herniation, ligament hypertrophy or ossification. Collec-
tively these disorders are referred to by the encompassing term of degenerative cervical mye-
lopathy [DCM]. [1] Symptoms often start with mild pain, loss of digital dexterity and subtle
gait disturbances but typically progress, with tetraplegia a potential extreme. DCM is estimated
to be the most common cause of spinal cord dysfunction worldwide. [2] In an Asian popula-
tion 4 in 100,000 underwent surgery for DCM annually. [3] Given its prevalence in the elderly
and with an aging population, its incidence is predicted to rise. [4]
Surgical decompression, to alleviate cord compression and prevent deficit progression, is
the mainstay of current treatment. However, many controversies persist, including the type
and timing of surgery, leading to wide ranging variation in practice. [5]
The emergence of an optimum treatment strategy has been complicated by the heteroge-
neous outcome measures used across the globe, introducing publication bias, hampering inter-
study comparison and guideline creation. [6,7] This is a recognised challenge in many clinical
fields and has lead to the development of minimum data sets, which consist of agreed, stan-
dardised set of data elements that should be measured and reported in a specific field of health-
care. [8]
Various methods have been developed to generate such data sets. A first step is often a sys-
tematic review, to identify the range of outcomes used in the literature. The list of reported out-
comes is subsequently refined using a structured consensus process including all relevant
parties; clinicians, academics, allied care professionals, patients and carers.[9,10] The latter
stakeholders are key to ensuring outcomes are patient centred.[11] Organisations such as the
COMET [Core outcome measures in effectiveness trials] initiative have been setup to facilitate
the process. [12]
The objectives of this study were therefore to describe the range of outcome measures, and
the manner in which they are reported, in studies of DCM, to inform a subsequent consensus
study. The current work complements and extends a recent narrative review of ancillary out-
come measures in DCM. [13]
Method
The systematic review was conducted in accordance with the PRISMA guidelines (S1 Table)
and registered with the PROSPERO prospective register of systematic reviews
(CRD42015025497).[14] MEDLINE [Ovid] and Embase [Ovid] databases, from 1st January
1995 to 12th August 2015 were searched using the search strategy [‘Cervical’] AND [‘Myelopa-
thy’] for articles considering myelopathy secondary to subacute compression. Animal studies,
case reports and letters/editorials were excluded.
Titles and abstracts were screened for relevance, with subsequent full text articles sought
and screened for eligibility according to the following criteria;
• English, full text
• Prospective study with>50 patients or retrospective study with>200 patients
• Assessment of clinical outcomes in response to a treatment stratagem (conservative or
interventional)
Articles were screened by two authors [BMD, AE] and data were extracted independently
by two authors [BMD, MM] using a piloted proforma. Discrepancies were settled by discussion
and mutual agreement. (S2 Table, S3 Table)
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Descriptive statistics were used to report frequency and proportion of outcome measures.
When considering the reporting method of a single instrument, proportions were presented as
the percentage of studies, which had used that instrument.
Results
Of the 6894 articles identified, 4261 articles were excluded based on our criteria. Following
abstract and title review, 170 articles were shortlisted (S2 Table) and their full published manu-
scripts reviewed. Of these, 108 were included in this study (S3 Table), assessing 23, 876 patients
[Fig 1]. The majority of studies were conducted in North America (33, 31%), Japan (28, 26%)
or other parts of Asia (36, 33%). Seventeen (16%) studies were randomised controlled trials
and 91 (85%) were conducted prospectively. Publication rate, including the proportion of pro-
spective studies and randomised controlled trials increased over time [Fig 2]. 105 [97%] studies
Fig 1. PRISMA flow diagram of the search strategy.
doi:10.1371/journal.pone.0157263.g001
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considered patients undergoing surgery, including one study assessing CT guided treatment of
disc herniation. The remaining studies considered conservative management.
Identified outcomes could be categorised into five common domains; function (reported by
97, 90% of studies), complications (reported by 56, 52% of studies), quality of life [QOL]
(reported by 31, 29% of studies), pain (reported by 29, 27% of studies) and imaging (reported
by 59, 55% of studies) outcomes (Table 1). Seventy-sex (70%) of studies considered more than
one domain. Only 7 (7%) studies considered all of domains in a single publication, 6 of which
were RCTs.
Function
Function was clinically assessed in 97 (90%) of studies, of which 35 (32%) used more than one
tool. The Japanese Orthopaedic Association assessment [JOA], functional and neurological
assessments, was most prevalent (50, 46%). Common alternatives included the gait and mobil-
ity-centric Nurick score (25, 23%), modified JOA [mJOA], an adaption of the JOA for the non-
Asian population (20, 19%), and the patient-reported Oswestry Neck Disability Index [NDI]
scales (20, 19%). The new JOA cervical myelopathy evaluation questionnaire, which in essence
combines the mJOA with the SF-36, was used in 3 (3%) studies. The popularity of these grading
Fig 2. Trends in published research. Stacked line graph of year of publication of identified studies. Retrospective studies are in blue, prospective studies in
red and the number of RCTs indicated by the black line. [Pro: Prospective, Retro: Retrospective, RCT: Randomised Controlled Trial]. The number of
publications has increased over time, including those deemed of higher quality (prospective and randomised).
doi:10.1371/journal.pone.0157263.g002
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systems changed over time (Fig 3) with the use of the JOA declining, in favour of mJOA and
Nurick.
Geographical variation was noted in the choice of functional assessment (Fig 4). For exam-
ple Japanese studies predominantly used the JOA assessment, whereas this was never used in
North American studies.
Table 1. Outcome domains identified by this systematic review.
Outcome Domain Number of studies including outcome domain (%)
Function 97 (90%)
Complications 56 (52%)
Quality of Life 31 (29%)
Pain 29 (27%)
Imaging 59 (55%)
All 7(7%)
doi:10.1371/journal.pone.0157263.t001
Fig 3. Variation in chosen functional outcomes overtime. Each bar represents 100%. The use of the most prevalent outcomemeasures (JOA, Nurick,
NDI, mJOA, JOACMEQ) are reported as percentages for each time period.
doi:10.1371/journal.pone.0157263.g003
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Other functional outcome assessments included Odom’s Criteria (8, 7%), “Neurological
Success” dichotomised to the same/better or worse from examination findings (6, 6%), return
to work (3, 3%) and the patient-reported Myelopathy Disability Index (2, 2%). Grip and release
assessment, 30m walking test, Neurosurgical Cervical Spine Score, Mean Locomotion Score,
Grip Strength, Neck range of movement and the Ranawat classification of disease severity fea-
tured once only.
The JOA was mostly reported as an overall mean (42, 84%) with or without a standard devi-
ation (38, 76%). Most, additionally reported the JOA recovery rate (34, 68%), first described by
Hirabayashi et al (1981). [15] The recovery rate was reported uniquely in two cases. Alterna-
tives include mean difference and categorised reporting. Components of the JOA were also
reported and sub-analysed in four studies (8%).
The method of reporting the Nurick grade had greater variability. Half reported a mean (13,
52%), often with standard deviation or 95% confidence intervals. Others reported subcatego-
ries, such as proportion of patients with improvement (9, 36%). The Nurick recovery rate was
used twice.
Fig 4. Geographical variation in chosen functional outcomes. Each bar represents 100%. The use of the most prevalent outcomemeasures (JOA,
Nurick, NDI, mJOA, JOACMEQ) are reported as percentages for each territory.
doi:10.1371/journal.pone.0157263.g004
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The mJOA was generally reported as a mean (15, 75%), with or without standard deviation
(8, 40%). In addition values were categorised (8, 40%), presented as mean difference (2, 10%)
or using a recovery rate formula (1, 5%). On three occasions, the postoperative mJOA was only
reported as a categorised value.
The NDI was generally reported as a mean (15, 75%), with or without standard deviation
(10, 50%). Alternatives were mean difference (6, 30%) or proportion achieving a predefined
improvement (3, 15%).
Complications
56 (52%) of studies reported intervention complications. This could simply be a description of
their overall frequency or a specific breakdown. Reported specific complications included C5
palsy, dysphagia, dysphonia, dural tear, CSF leak, surgical site infection and haematoma. Mor-
tality, even if absent, was infrequently reported (15, 14%). The requirement for revision sur-
gery, either immediate or delayed, was reported in 27 (25%) studies.
Quality of Life
QOL was reported by 31 (29%) of studies. The Medical Outcome Short Form Health Survey
[SF-36] was the predominant QOL measure used (25, 23%). The more recently developed, Jap-
anese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire [JOACMEQ]
was only used in 3 (3%) of studies. Other outcome measures included the EQ-5D (2, 2%) and
the 12-item Short Form Health Survey [SF-12] (2, 2%).
The method of reporting the SF-36 varied; 9 (36%) calculated and reported each of the 8
component scores [vitality, physical functioning, bodily pain, general health perceptions, phys-
ical role functioning, emotional role functioning, social role functioning and mental health],
whereas 9 (36%) reported the mental [MCS] and physical [PCS] component summary scores
only. Other options included reporting only the PCS (3, 12%), the overall score (3, 12%) or
everything (1, 1%).
Pain
Pain was assessed in 29 (27%) of studies. With the exception of one study, it was reported via
an assessment method distinct to a QOL tool. Pain was most commonly measured using the
10cm Visual Analogue Scale [VAS] (21, 19%). Alternatives included a numeric rating scale (1,
1%), Likert scale (2, 2%) or consultation questions as simple as “Do you have any pain, yes or
no?”
In general pain assessment was focused (24, 22%); 17 (16%) considered upper limb pain, 22
(20%) neck pain and 9 (8%) axial pain. The term axial pain is ambiguous and it was rarely
defined. One study considered it to include neck and shoulder pain, whereas another made a
distinction between neck and ‘axial symptoms’.
The reporting of the VAS also varied. The majority (17, 81%) reported a mean and standard
deviation before and after, with statistical comparison by a T Test. This was despite distribution
analysis being reported on only 4 occasions. Alternative reporting included the percentage of
patients who attained a>20mm improvement (2, 12%).
Imaging
A total of 59 (55%) of studies reported radiological outcomes. Assessments were predomi-
nantly made using X-rays (46, 43%). CT (23, 21%) and MRI (19, 18%) were used less com-
monly. Radiological outcomes largely concerned fusion (29, 49%), range of movement (25,
Outcome Measures Use in Cervical Myelopathy
PLOS ONE | DOI:10.1371/journal.pone.0157263 August 2, 2016 7 / 12
42%), cervical alignment (25, 42%) and decompression (15, 25%). The exact definition of
fusion and assessment of range of movement was variable. Cervical alignment was largely
assessed using Cobb’s method (14, 56%) or the Ishihara’s Cervical Curvature Index (7, 28%).
Decompression generally referred to adequate cord decompression assessed by MR (8, 53%).
Alternative metrics pertain to changes in canal size.
Additional outcome measures included adjacent segment degeneration (3, 5%) or novel MR
cord metrics pertaining to cord signal intensity, cross sectional area and ‘drift back’ (4, 4%).
Other
Some studies reported treatment characteristics including length of operation (23, 21%), blood
loss (22, 20%) and length of hospital (8, 7%). Cost of Care was reported twice (2%).
Randomised Controlled Trials
Overall there were 17 RCTs, and the mean number of domains they reported was significantly
greater than other studies (3.9 vs. 2.3) (Table 2).
A functional outcome was reported by all RCTs. Four RCTs reported more than one func-
tion assessment, and chosen assessments were typically the JOA (8, 47%) or NDI (7, 41%).
Complications were reported by 15 (88%) and QOL by 8 (47%) of studies. The favoured QOL
measure was the SF-36, used by 7 of these. Pain was assessed by 11 (65%) of studies, typically
using the VAS (9, 82%). Radiographic outcomes were reported by 16 (94%) of RCTs
Discussion
This systematic review has identified that DCM is a topic of world-wide interest, with research
participation from all corners of the globe. However, there is great variation in the types of out-
comes assessed and how they are reported. Key outcome domains were function (most com-
monly reported using the JOA), QOL (most commonly reported using the SF-36), treatment
complications, pain (most commonly reported using the 10cm VAS) and imaging. Very few
studies considered them all. RCTs reported more domains than other types of study and typi-
cally, when considering a domain, were more consistent in their choice of reporting.
This heterogeneity is not surprising, a survey by Singh et al (2005) of clinicians found great
variability in the assessment and grading of DCM.[16] Equally it has been well demonstrated
in other fields of health care. [17–19] Heterogeneity of outcome reporting is recognised to chal-
lenge inter study comparison and likely lead to bias in the dissemination of knowledge. [20] To
overcome these challenges the development of standardised reporting sets has been proposed.
Similarly, the present findings of this study provide a strong basis for the development of a
standardised reporting set in DCM. [7,10,17]
Limitations
The search results demonstrate that cervical myelopathy is a feature of much published
research. The search strategy excluded foreign language articles and was designed to focus on
contemporary and large sample studies. The global representation of included studies suggests
that the foreign language exclusion is unlikely significant. Indeed, the authors propose that
assessment of 20 years of published data of large sample studies, is representative of current
practice.
Beyond demonstrating heterogeneity, this study aimed to collate current reporting practice,
to help inform stakeholders of a future DELPHI process. When interpreting these results, it is
therefore important to recognise that only outcome measures previously used will be
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represented. This poses a few potential problems. First, more recently developed assessment
tools could be underrepresented (e.g JOACMEQ).[21] Second, the measurement properties of
these scales have not been assessed here, nor whether there is current rational for the measured
outcomes. Third, novel areas of assessment will not be represented.
In relation to this latter aspect, it is significant that patient reported outcomes [PROMs] and
preference-based outcomes, topical areas for current trial development and funding[22], were
poorly represented (33, 31%). The significance of patient involvement in research has become
more apparent in recent years. Chalmers et al (2014) found 85% of US health research funding
Table 2. Outcome domains reported by Randomised Controlled Trials.
Article Function Complications QOL Pain Imaging
Ying et al 2007 JOA Reported Fusion
Alignment
Other
Riew et al 2008 Nurick Reported SF-36 VAS
NDI
*Goffin et al 2010 NDI Reported SF-36 SF36 Pain Score Alignment
ROM
Lian et al 2010 JOA Reported VAS Alignment
Fusion
*Park et al 2011 Other
Wan et al 2011 JOA NRS Alignment
Fusion
ROM
Sun et al 2011 JOA Reported Fusion
Other
Sasso et al 2011 NDI Reported SF-36 VAS Alignment
Cheng et al 2011 JOA Reported SF-36 ROM
NDI
Zhang et al 2012 NDI Reported VAS ROM
Wang et al 2012 JOA Reported SF-36 VAS Alignment
Other
Phillips et al 2013 Nurick Reported SF-36 VAS ROM
NDI Fusion
Nakashima et al 2014 JOA Reported Alignment
ROM
Other
Mashadin et al 2014 Nurick Reported Fusion
Other
Xie et al 2015 JOA Reported VAS Fusion
Alignment
Other
Phillips et al 2015 Nurick Reported SF-36 VAS ROM
NDI Other
Jeyamohan et al 2015 mJOA Reported SF-12 VAS Fusion
*Indicates substudy based on RCT data.
VAS Visual Analogue Scale, NDI Oswestry Neck Disability Index, JOA Japanese Orthopaedic Association, NRS Numeric Rating Scale, ROM Range of
Movement.
doi:10.1371/journal.pone.0157263.t002
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was wasted and concluded one of many contributing factors was the misalignment of research
objectives with patient needs.[23] Consequently PROMs are now an important aspect of trial
funding applications.
The significance of preference-based outcomes in trials is largely to allow economic analysis
via the derivation of metrics such as quality adjusted life years [QALY]. In practice, the gold
standard preference-based tests (such as standard gamble and time trade off) are replaced by
utility instruments, to infer cost utility indirectly. These utility instruments are generally quality
of life measures.[24] The most commonly used scales are the EQ-5D and SF-6D.[22] Whilst
the SF-36 can act as a utility instrument, typically it requires derivation of the SF-6D to do so.
[25] The UK advisory body for government funded healthcare, NICE, recommends the EQ-5D
for cost utility assessment, when considering treatments for approval.[26]
Future Directions
As stated in the introduction, this systematic review is the starting point for a larger process, to
define the core outcomes and common data elements in degenerative cervical myelopathy
[CODE-DCM]. The study aims to identify the key data elements, to advise on how they should
be reported and to identify the umbrella term by which this disease process should be referred.
It is registered with the COMET initiative.[27]
The results of this process will be to allow efficient and effective inter-study comparison, to
support future research and the development of an optimum treatment.
The findings of this systematic review, alongside further planned work, will be used to
inform a DELPHI process, made up of key stakeholders representing patients, carers, profes-
sionals and industry.[9]
Conclusions
Significant heterogeneity exists in the outcome reporting of studies assessing management of
DCM. The development of a standardised, reporting set would support the field in the future.
The findings of this study will be used as part of a larger consensus process to define the core
outcomes and data elements in degenerative cervical myelopathy [CODE-DCM].
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